CMO Research Review, By Dr. Gonzzo Watson

Cerosomal-cis-9-cetylmyristoleate (CMO).  CMO  shows promise as a great new nutrient for those suffer from arthritic conditions, especially autoimmune diseases like rheumatoid arthritis.  An autoimmune disorder is when your body produces antibodies against itself.  In other words you attack your own normal tissues.  It appears CMO may reprogram the immune cells not to attack as is the case in rheumatoid arthritis.  In a placebo controlled trial of 431 patients conducted by Siemandi, 58% of patients taking CMO showed 75% improvement in arthritic conditions¹.

When a medical researcher named Harry Diehl induced joint trauma to start arthritis in mice and rats, the mice would not get arthritis and the rats would.  He found mice have CMO naturally and rats don't.  When he gave CMO to the rats they too did not get arthritis².

There are many other favorable reports^3,4,5 for this newly introduced supplement.  I recommend it highly for arthritic conditions.

Dr Watson

• 1. "The effect of CMO and adjunctive therapy on arthritis and autoimmune disease: a randomized trial," TLfD&P Aug Sept 1997:59-63.
• 2.  Levy, CMO, A 21^st Century Solution to Arthritis. An Extraordinary Story about Cetyl Myristoleate, Santa Barbara, CA: JKM Enterprises, 2000: Chap 6
• 3.  Trials conducted by William Freshwater, DC (The American Chiropractor 1999:21(3):17-19
• 4.  The Townsend Letter for Doctors and Patients. Aug-Sept 1997:59-63
• 5.  A clinical study monitored by the San Diego Clinic (Sands, L. Arthritis Defeated at Last. Acquarius Holdings, Ltd. 1998). The San Diego clinic describes many favorable anecdotal (case histories and personal reports) stories of the beneficial effects of CMO.